AstraZeneca’s Soliris Gains Approval in China for NMOSD Treatment
UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has announced that its rare disease drug...
CNIPA Upholds Alnylam’s PCSK9-Targeted siRNA Patent Against Junshi Biosciences Challenge
The China National Intellectual Property Administration (CNIPA) has rejected another challenge from Junshi Biosciences (SHA:...
Qilu Pharmaceutical Presents Promising Data for QL1706 and QL1209 at ESMO 2023
China-based Qilu Pharmaceutical has announced the presentation of clinical data for two of its pipeline...
Guangdong Zhongsheng Launches AI Q&A Bot for Leritrelvir Drug Support
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the innovative launch of a...
WuXi XDC Partners with Hong Kong Science Park to Boost CRDMO Value Chain
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary...
AlphaGen Therapeutics Secures Seed Funding for Pb-212 Radioligand Therapy Development
AlphaGen Therapeutics Ltd, a Shanghai-based developer specializing in radioligand therapy (RLT), has reportedly secured “tens...
Boehringer Ingelheim’s Vitiligo Drug EI-001 Approved for Clinical Trials by NMPA
Germany’s Boehringer Ingelheim (BI) has announced that the National Medical Products Administration (NMPA) has approved...
Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759)...
Haisco Pharmaceutical’s HSK21542 Accepted for NMPA Review in Postoperative Pain Management
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...
NMPA Issues Guidelines for Temporary Import of Urgently Needed Medical Devices
The National Medical Products Administration (NMPA) has released new “Management Requirements for Temporary Import and...
Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand
Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year...
Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial
Roche (SWX: ROG) subsidiary Genentech has revealed preliminary but promising results from a Phase III...
Eli Lilly Acquires Mablink Bioscience to Expand Next-Gen ADC Portfolio
US pharmaceutical company Eli Lilly (NYSE: LLY) has signed an agreement to acquire France-based Mablink...
Belief BioMed Partners with Takeda for BBM-H901 Commercialization in Asia
Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced a strategic partnership with Japan’s...
MicuRx Pharmaceuticals Initiates Phase I Study for MRX-5 in Australia
Sino-US firm MicuRx Pharmaceuticals Inc. has announced the approval to conduct a Phase I clinical...
GenScript Reports $152 Million in Sales for Carvykti as of September 30, 2023
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
Novartis Launches Leqvio in China at RMB 9,988 per Shot
Swiss pharmaceutical giant Novartis (NYSE: NVS) has officially launched its cholesterol-lowering drug, Leqvio (inclisiran), in...
Zhejiang Huahai Pharmaceutical Secures Orphan Drug Designation for HB0034
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received orphan...
Merck KGaA Partners with Porton Pharma for Next-Gen ADC Platform Development
German pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a strategic partnership with China-based...
Lepu Medical Gains NMPA Approval for Semi-Automatic External Defibrillator
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...